ProKidney Corp (PROK)
NASDAQ (CM) NASDAQ (CM) Primary Summary
ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade)
ProKidney Corp. is a single-asset biotech with a dwindling cash position and an unproven lead therapy, rilparencel. Phase 2 data for rilparencel is weak, with confounding factors and no robust evidence of efficacy; Phase 3 PROACT data in 2027 is pivotal. PROK's cash runway extends only into mid-2027, with just $181.6M remaining and ongoing high cash burn, raising 'going concern' doubts.
ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates
ProKidney Corp. (PROK) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
ProKidney Corp. (PROK) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.
ProKidney Corp Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BG Bart Gancher Intech Investment Management LLC | 16,942 | $32,020.38 | $27,784.88 | -$4,235.5 | -13.23% |
| JM John Malone Amundi | 304,151 | $668,183.49 | $514,015.19 | -$154,168.3 | -23.07% |
| PF Phillip Fitzsimmons Hennion & Walsh Asset Management Inc. | 1.85M | $4.17M | $3.53M | -$644,206.96 | -15.44% |
 Joseph Castro Nuveen LLC | 101,461 | $191,761.29 | $193,283.2 | $1,521.91 | 0.79% |
 Dinan Hu R Squared Ltd | 17,822 | $32,314.14 | $33,861.8 | $1,547.66 | 4.79% |
ProKidney Corp (PROK) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ProKidney Corp ever had a stock split?
ProKidney Corp Profile
| Biotechnology Industry | Healthcare Sector | Bruce Culleton CEO | NASDAQ (CM) Exchange | 74291D104 CUSIP |
| US Country | 231 Employees | - Last Dividend | - Last Split | 12 Jul 2022 IPO Date |
Overview
ProKidney Corp. is a pioneering entity in the biotechnology sector, focusing its efforts on the advancement of cell therapy platforms aimed at the amelioration of chronic kidney diseases. With its inception in 2015, the company has dedicated itself to developing innovative therapeutic solutions from its headquarters in Winston-Salem, North Carolina, USA. The primary mission of ProKidney Corp. is to introduce groundbreaking treatments that offer hope and improved outcomes for patients suffering from various kidney ailments, leveraging the vast potential of cell therapy technologies.
Products and Services
- Renal Autologous Cell Therapy (REACT):
This flagship product embodies the core of ProKidney Corp.'s innovative approach towards tackling chronic kidney diseases. REACT is a cutting-edge therapeutic modality based on the use of autologous homologous cell admixtures. This treatment has successfully completed its Phase I clinical trial, targeting patients with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT). Building upon this initial success, REACT has progressed to Phase III and Phase II clinical trials for addressing moderate to severe diabetic kidney disease, highlighting its potential as a transformative solution for a widespread and impactful health challenge.
